19 assets in Acral Lentiginous Melanoma

Therapeutic assets addressing Acral Lentiginous Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab Acral Lentiginous Melanoma	Yonsei University	P2	BB (65)
Nivolumab Acral Lentiginous Melanoma	Fred Hutchinson Cancer Center	P2	B (62)
Rivoceranib Acral Lentiginous Melanoma	Peking University Cancer Hospital & Institute	P3	B (62)
Catequentinib Acral Lentiginous Melanoma	Qilu Hospital of Shandong University	P2	B (60)
Ipilimumab Acral Lentiginous Melanoma	Emory University	P2	B (57)
Binimetinib Acral Lentiginous Melanoma	SWOG Cancer Research Network	P2	CCC (53)
Dinaciclib Acral Lentiginous Melanoma	National Cancer Institute (NCI)	P2	CCC (53)
Encorafenib Acral Lentiginous Melanoma	SWOG Cancer Research Network	P2	CCC (53)
Endostatin Acral Lentiginous Melanoma	Fudan University	P2	CCC (53)
Toripalimab Acral Lentiginous Melanoma	Fudan University	P2	CCC (53)
Tuvoraleimab Acral Lentiginous Melanoma	Fudan University	P2	CCC (53)
Vactosertib Acral Lentiginous Melanoma	Yonsei University	P2	CCC (49)
Mdna11 Acral Lentiginous Melanoma	Medicenna Therapeutics, Inc.	P1/2	CC (45)
Cyclophosphamide Acral Lentiginous Melanoma	Anusha Kalbasi	P1	CC (44)
Fludarabine Acral Lentiginous Melanoma	Anusha Kalbasi	P1	CC (44)
Tbio-4101 Acral Lentiginous Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (44)
Autologous Anti-Cd19 Car-Expressing T Lymphocytes Acral Lentiginous Melanoma	Anusha Kalbasi	P1	CC (41)
Fludeoxyglucose Acral Lentiginous Melanoma	Anusha Kalbasi	P1	CC (41)
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells Acral Lentiginous Melanoma	Anusha Kalbasi	P1	CC (41)